On June 15, 2021, Infinovo Medical, a leading enterprise in the continuous glucose monitoring (CGM) industry, announced that it had recently completed a Series C financing of hundreds of millions of yuan, led by Hillhouse Capital and Taifu Capital, with Yunfeng Fund, Zhengxin Valley Capital, Zhongyuan Qianhai Fund, Huimei Capital, Juming Venture Capital, and Life Capital following suit. Life Capital serves as the exclusive financial advisor for this round of financing. This round of financing will mainly be used to further promote the company's product research and development, market promotion, and expand reproduction.

Infinovo Medical was founded in 2016 and is a global innovative enterprise dedicated to continuous glucose monitoring (CGM) product technology. Its production base is located in Nantong, Jiangsu, with technology research and development centers in Suzhou and London, and an overseas sales center in Amsterdam, the Netherlands. In the five years since its establishment, Infinovo Medical has achieved rapid and leapfrog development, focusing on breakthrough research in semi permeable membrane materials, dehydrogenase technology, blood glucose prediction algorithms, data mining and interaction, soft needle delivery systems, wireless transmission systems, and ecosystems. All parameters of the company's CGM products have reached industry-leading levels. As of 2020, the company's products have been sold in 15 overseas countries and are about to enter the Chinese domestic market.

At present, the company is accelerating the construction of a global production base, and it is expected to build the world's first fully automated production line based on dehydrogenase technology and printing technology by 2023, with a designed production capacity of 12 million pieces per year. At that time, Infinovo Medical is expected to become the world's first CGM commercial mass production enterprise based on dehydrogenase technology.

Mr. Cheng Rongen, founder of Infinovo Medical, stated that in the future, Infinovo Medical will rely on its Suzhou R&D center to build a global R&D system. It will establish a CGM ecological algorithm research center in London, a sensor semi permeable membrane material laboratory in California, and a physiological parameter weak signal processing research center in Beijing. Through continuous independent R&D and innovation, Infinovo Medical will be committed to promoting the application of CGM product technology in more fields, enabling the whole industrial chain related to diabetes management and nursing.